Yubo International Biotech Limited reported a significant increase in revenue for the fiscal year ending December 31, 2025, generating $12.4 million, a 256% rise from $3.5 million in 2024. Despite this growth, the company continues to face substantial losses, with a net loss of $1.2 million for 2025, down from $2 million in the previous year. The increase in revenue was attributed to sporadic sales of its health management services and light application products, although the overall sales volume remains low.
The company's operating expenses decreased by 33% to approximately $1.2 million, primarily due to reduced occupancy costs following the early termination of a lease. This reduction in expenses contributed to a smaller loss from operations, which was reported at $1.2 million, compared to $1.8 million in 2024. The decrease in other expenses, particularly the absence of losses on obsolete inventory that impacted the previous year, also played a role in improving the financial outcome.
Yubo International Biotech has made strategic moves to enhance its market position, including the acquisition of a 70% equity interest in EpiAis Biomedical Engineering and the establishment of a stem cell storage facility, which is expected to be the first of its kind globally. The company aims to expand its product offerings under the "VIVCELL" brand, which includes healthcare products and stem cell-related services. However, the company relies heavily on a limited customer base, with one customer accounting for 100% of its total sales in 2025, raising concerns about revenue stability.
As of December 31, 2025, Yubo International Biotech reported total assets of $847,094 and total liabilities of $2.8 million, resulting in a significant shareholders' deficit of approximately $1.9 million. The company has a negative working capital of $2.1 million, indicating ongoing liquidity challenges. To address these issues, Yubo has secured a financial support letter from its largest shareholder, Jun Wang, committing to provide continuous financial support for the next 12 months.
Looking ahead, Yubo International Biotech's management acknowledges the need for additional capital to sustain operations and fund future growth. The company plans to explore new financing options while continuing to develop its product lines and expand its market presence. However, uncertainties regarding regulatory compliance in China and the potential impact of geopolitical tensions on its operations remain significant risks that could affect the company's future performance.
About Yubo International Biotech Ltd
Yubo International Biotech Limited is a U.S.-based holding company focused on biotechnology, primarily operating through its subsidiaries in China. It develops and commercializes stem cell storage, healthcare, and personal care products, leveraging proprietary stem cell technology. The company emphasizes research, product development, and building a stem cell bank, serving health management, anti-aging, and regenerative medicine markets with a competitive edge in endometrial stem cell applications.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.